Lost password ?
<< Back to Equity Research
Gulf Pharmaceutical
JULPHAR, NEEDS A "FACELIFT"
Sep 26 - We were optimistic on Julphar (Reduce, UAE)’s outlook in our last paper of February, however achievements since then were disappointing. The share price has bottomed to Covid-crisis levels, already ...
Executive summary
Conflict of Interest
Pages 40
Language English
Publish on September 26, 2023
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 29 PM
SIPHAT
The mess continues
Apr 29 PM
SIPHAT
Declining revenue
Apr 25 AM
UNIMED
Double-digit growth in Q1
Apr 15 PM
Idea Kicker
JULPHAR, WAITING FOR A SAFETY MARGIN
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ